Market open
Day One Biopharmaceuticals/$DAWN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
Ticker
$DAWN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
181
Website
DAWN Metrics
BasicAdvanced
$781M
-
-$1.02
-1.46
-
Price and volume
Market cap
$781M
Beta
-1.46
52-week high
$18.07
52-week low
$7.52
Average daily volume
1.4M
Financial strength
Current ratio
7.656
Quick ratio
7.428
Long term debt to equity
0.516
Total debt to equity
0.518
Management effectiveness
Return on assets (TTM)
-27.67%
Return on equity (TTM)
-22.49%
Valuation
Price to revenue (TTM)
5.481
Price to book
1.55
Price to tangible book (TTM)
1.6
Price to free cash flow (TTM)
-4.717
Growth
Earnings per share change (TTM)
-56.78%
3-year earnings per share growth (CAGR)
-39.46%
What the Analysts think about DAWN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Day One Biopharmaceuticals stock.
DAWN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DAWN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DAWN News
AllArticlesVideos
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
GlobeNewsWire·1 month ago
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Day One Biopharmaceuticals stock?
Day One Biopharmaceuticals (DAWN) has a market cap of $781M as of April 04, 2025.
What is the P/E ratio for Day One Biopharmaceuticals stock?
The price to earnings (P/E) ratio for Day One Biopharmaceuticals (DAWN) stock is 0 as of April 04, 2025.
Does Day One Biopharmaceuticals stock pay dividends?
No, Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Day One Biopharmaceuticals dividend payment date?
Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders.
What is the beta indicator for Day One Biopharmaceuticals?
Day One Biopharmaceuticals (DAWN) has a beta rating of -1.46. This means that it has an inverse relation to market volatility.